Syndax Pharmaceuticals advances Revumenib for relapsed AML with FDA decision pending. See why SNDX stock is a key player in ...
particularly by inhibiting a specific cancer-driving protein within the complex—BPTF—could provide a new approach to treating ...
Syndax Pharmaceuticals (SNDX) stock dropped ~23% after the company posted Phase 2 trial data for its AML candidate, revumenib ...
In the phase 2 portion of the phase 1/2 AUGMENT-101 trial, 12 of 64 patients with relapsed or refractory mutant NPM1 acute ...
1don MSN
Researchers from the Tumor Profiler consortium have combined single-cell multi-omics and functional profiling for 21 AML ...
Syndax (SNDX) announced positive topline results from the relapsed or refractory mutant NPM1 – mNPM1 – acute myeloid leukemia, or ...
Reported 100% of Acute Myeloid Leukemia (AML) patients treated in INB-100 remain in complete remission (CR) at the 2024 ...
Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced positive topline results from the relapsed or ...
In addition to developing WU-CART-007, a drug candidate in clinical trials for treating relapsed or refractory T-cell acute ...
The study is testing the drug in certain patients with relapsed or refractory acute myeloid leukemia (AML). The small ...
On Tuesday, Syndax Pharmaceuticals Inc (NASDAQ:SNDX) revealed topline results from the relapsed or refractory (R/R) mutant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback